- Page 1 and 2: Impurities, Adulteration, and the C
- Page 3 and 4: A Fifteen Year Saga Begins � 1995
- Page 5 and 6: Recent Activities � USP published
- Page 7 and 8: Design and Scope of Chapters � Li
- Page 9 and 10: Impurities and Limits - Current Pan
- Page 11 and 12: Some Possible Scenarios Added to th
- Page 13 and 14: Results of Team’s Experiments �
- Page 15 and 16: Elemental Impurities-Procedures Qu
- Page 17 and 18: Stimuli Article: Elemental Impuriti
- Page 19 and 20: Acknowledgements Heavy Metals Advis
- Page 21: TOXIC METALS / METALLOIDS REPORTED
- Page 26 and 27: LEAD EXPOSURE IN THE GENERAL U.S. P
- Page 28: AMINO ACID COMPOSITIONS KIDNEY PbBP
- Page 33 and 34: POTENIAL SIGNIFICANCE OF LEAD LEAD-
- Page 35 and 36: Pharmaceutical Applications of Atom
- Page 37 and 38: Advantages and Disadvantages of Fla
- Page 39 and 40: ICP-MS • Advantages � Very rapi
- Page 41 and 42: Laser Induced Breakdown Spectroscop
- Page 43 and 44: Proposed Chapter • Companion cha
- Page 45 and 46: What’s Next? • USP to publish r
- Page 47 and 48: Introduction Contents Toxicity of D
- Page 49 and 50: Types of Inorganic Impurities 4
- Page 51 and 52: Controls on Heavy Metals (HM): USP
- Page 53 and 54: Controls on Heavy Metals (HM) & Lea
- Page 55 and 56: EEvaluation l ti of f Acceptable A
- Page 57 and 58: Dose Levels - NOEL no no-observed o
- Page 59 and 60: Reference Dose (RfD) �An estimate
- Page 61 and 62: Dose-Response Curves (non-carcinoge
- Page 63 and 64: Massachusetts Bay Law Law, Septembe
- Page 65 and 66: Lead as impurities in food or drug
- Page 67 and 68: Lead in pharmaceutical products and
- Page 69 and 70: The Relationship Between Blood Lead
- Page 71 and 72: Acute • GI effects - colic, sever
- Page 73 and 74:
Elemental Mercury Found in mercury
- Page 75 and 76:
How can Elemental Mercury Enter the
- Page 77 and 78:
Inorganic Mercury Poisoning • Gas
- Page 79:
A 27 y.o. male resident of Ramnigar
- Page 82 and 83:
Itai Itai-Itai Itai or “ouch “o
- Page 84 and 85:
• NOAEL = 5 µg/kg/day • UF = 1
- Page 86 and 87:
Proposed Limits (Oral) Elements USP
- Page 88 and 89:
Proposed Limits (O (Oral) ) Element
- Page 90 and 91:
Points to consider: What concentrat
- Page 93 and 94:
Current and Future Directions and I
- Page 95 and 96:
Compendial Challenges for Biologica
- Page 97 and 98:
Definition - key elements • What
- Page 99 and 100:
Identification and the “Absence o
- Page 101 and 102:
Strategy for B&B Product Classes Mo
- Page 103 and 104:
11/29/2010 11
- Page 105 and 106:
Clinical uses of heparin • Treatm
- Page 107 and 108:
What was the contamination problem?
- Page 109 and 110:
Potential characterization methods
- Page 111 and 112:
Orthogonal methods • Orthogonal m
- Page 113 and 114:
OSCS contaminated heparin • How d
- Page 115 and 116:
Extracted OSCS from 0099‐D01 1 H
- Page 117 and 118:
Acknowledgements • Carolyn Swann
- Page 119 and 120:
History of adulteration with Diethy
- Page 121 and 122:
FDA Request • April 2007: FDA req
- Page 123 and 124:
Comments from CDER Office of Compli
- Page 125 and 126:
REVISION BULLETTIN IPR Monograph mo
- Page 127 and 128:
11/29/2010 10
- Page 129 and 130:
Tragic Consequences Not If… But W
- Page 131 and 132:
• Collaborative Rx-360 Key Princi
- Page 133 and 134:
Rx-360.org Shares Technology That C
- Page 135 and 136:
To secure the supply chain 11. Firs
- Page 137 and 138:
Common sense dictates the use of ta
- Page 139 and 140:
There are many new ideas that can b
- Page 141 and 142:
To protect the patients you serve,
- Page 143 and 144:
Thank you For More Information 31 J
- Page 145 and 146:
Introduction Figure 1. Black Cohosh
- Page 147 and 148:
An Opportunity • To our knowledge
- Page 149 and 150:
Selection of Marker Compounds Sourc
- Page 151 and 152:
Region of Cimifugin (not detected)
- Page 153 and 154:
Results Marker Compound Actaea Othe
- Page 155 and 156:
Discussion (Cont’d) Important con
- Page 157 and 158:
Actions by the Regulator in Respons
- Page 159 and 160:
Actions by the Regulator in Respons
- Page 161 and 162:
Conclusion • By working together
- Page 163 and 164:
QUALITY CONTROL ON SAFETY AND EFFIC
- Page 165 and 166:
Study on analytical standards of Af
- Page 167 and 168:
Analysis of organic residues of mac
- Page 169 and 170:
Extractum Flos Lonicerae Siccus 1 2
- Page 171 and 172:
Substantial basis research achieve
- Page 173 and 174:
The standard characteristics chroma
- Page 175 and 176:
Frame of the quality standards stud
- Page 177 and 178:
�Extracting way The factors influ
- Page 179 and 180:
RRealgar l Cinnabar HPLC-ICP-MS Chr
- Page 181 and 182:
Correlation between in vitro and in
- Page 183 and 184:
Combating Counterfeiting and Substa
- Page 185 and 186:
Good Legislation and Regulation Unr
- Page 187 and 188:
The Regulatory Challenge Poor Regis
- Page 189 and 190:
Key Findings Nummber of Samples 16
- Page 191 and 192:
Addressing the Problem �Regulated
- Page 193 and 194:
Advantages of the Minilab � Requi
- Page 195 and 196:
Conclusion �Quality is not a luxu
- Page 197:
11/29/2010 14